Alexander Kulla

Merck’s MAVENCLAD Shows Sustained Reduction in Neuronal Injury for Multiple Sclerosis Patients

(IN BRIEF) Merck, a prominent science and technology company, has revealed new findings from the MAVENCLAD® (cladribine tablets) MAGNIFY-MS study…

7 months ago